Peng Luo

Orcid: 0000-0002-8215-2045

Affiliations:

Southern Medical University, Department of Oncology, Zhujiang Hospital, Guangzhou, Guangdong, China
Carol Yu Centre for Infection, Department of Microbiology, State Key Laboratory of Emerging Infectious Diseases, China
University of Hong Kong, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong
Central South University, Hypothalamic Pituitary Research Centre, Xiangya Hospital, Changsha, China

According to our database¹, Peng Luo authored at least 10 papers between 2022 and 2025.

Collaborative distances:

Dijkstra number² of four.
Erdős number³ of four.

Timeline

Legend:

Book

In proceedings

Article

PhD thesis

Dataset

Other

Bibliography

2025

Computational frameworks transform antagonism to synergy in optimizing combination therapies.

[BibT_eX]

[DOI]

npj Digit. Medicine, 2025

Bridging artificial intelligence and biological sciences: a comprehensive review of large language models in bioinformatics.

[BibT_eX]

[DOI]

Briefings Bioinform., 2025

2024

Inhibitory neuron links the causal relationship from air pollution to psychiatric disorders: a large multi-omics analysis.

[BibT_eX]

[DOI]

J. Big Data, December, 2024

PESSA: A web tool for pathway enrichment score-based survival analysis in cancer.

[BibT_eX]

[DOI]

PLoS Comput. Biol., 2024

CPADS: a web tool for comprehensive pancancer analysis of drug sensitivity.

[BibT_eX]

[DOI]

Briefings Bioinform., 2024

2023

BEST: a web application for comprehensive biomarker exploration on large-scale data in solid tumors.

[BibT_eX]

[DOI]

J. Big Data, December, 2023

Artificial intelligence learning landscape of triple-negative breast cancer uncovers new opportunities for enhancing outcomes and immunotherapy responses.

[BibT_eX]

[DOI]

J. Big Data, December, 2023

STAGER checklist: Standardized Testing and Assessment Guidelines for Evaluating Generative AI Reliability.

[BibT_eX]

[DOI]

CoRR, 2023

2022

Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma.

[BibT_eX]

[DOI]